Your browser doesn't support javascript.
loading
Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study.
Paris, Robert; Apter, Dan; Boppana, Suresh; D'Aloia, Maria; De Schrevel, Nathalie; Delroisse, Jean-Marc; Grassano, Luca; Guignard, Adrienne; Panackal, Anil A; Roman, Francois; Yu, Jing; Yunes, Elsa M; Dieussaert, Ilse.
Afiliación
  • Paris R; Vaccines, GSK, Rockville, Maryland, US.
  • Apter D; VL-Medi Clinical Research Center, Helsinki, Finland.
  • Boppana S; Departments of Pediatrics and Microbiology, University of Alabama at Birmingham, Birmingham, US.
  • D'Aloia M; Vaccines, GSK, Rixensart, Belgium.
  • De Schrevel N; Vaccines, GSK, Rixensart, Belgium.
  • Delroisse JM; Vaccines, GSK, Wavre, Belgium.
  • Grassano L; Vaccines, GSK, Siena, Italy.
  • Guignard A; Vaccines, GSK, Wavre, Belgium.
  • Panackal AA; Vaccines, GSK, Rockville, Maryland, US.
  • Roman F; Vaccines, GSK, Wavre, Belgium.
  • Yu J; Vaccines, GSK, Rockville, Maryland, US.
  • Yunes EM; Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico.
  • Dieussaert I; Vaccines, GSK, Wavre, Belgium.
J Infect Dis ; 228(11): 1491-1495, 2023 11 28.
Article en En | MEDLINE | ID: mdl-37340664
ABSTRACT
Developing a vaccine to prevent congenital cytomegalovirus (CMV) infection and newborn disability requires an understanding of infection incidence. In a prospective cohort study of 363 adolescent girls (NCT01691820), CMV serostatus, primary infection, and secondary infection were determined in blood and urine samples collected at enrollment and every 4 months for 3 years. Baseline CMV seroprevalence was 58%. Primary infection occurred in 14.8% of seronegative girls. Among seropositive girls, 5.9% had ≥4-fold increase in anti-CMV antibody, and 23.9% shed CMV DNA in urine. Our findings provide insights on infection epidemiology and highlight the need for more standardized markers of secondary infection.
Cytomegalovirus (CMV) can be passed from a woman to her unborn baby during pregnancy, which can result in disabilities in the baby. This can happen after a first infection with the virus during pregnancy, after a subsequent infection with a different strain ("reinfection"), or after "reactivation", which means that a virus present from a previous infection becomes active again. Vaccinating adolescent girls against CMV may be a future strategy to help prevent CMV infection during pregnancy. To provide information to design trials evaluating a CMV vaccine, it is important to know how common primary/secondary CMV infection is in adolescent girls and if this can be measured with available tools. We followed adolescent girls living in Finland, Mexico or the United States for three years. At study start, 58% of these girls showed evidence of previous CMV infection. During the three-year follow-up, a first CMV infection occurred in 15% of girls, and reinfection or reactivation in 6% to 24% of girls (depending on the method used). The obtained estimates of CMV infection rates in adolescent girls provide valuable information for future studies to evaluate CMV vaccines, but standardized markers for secondary infection are needed.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Citomegalovirus / Coinfección Tipo de estudio: Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Female / Humans Idioma: En Revista: J Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Citomegalovirus / Coinfección Tipo de estudio: Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Female / Humans Idioma: En Revista: J Infect Dis Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos